INTRODUCTION
Multiple myeloma (MM) almost exclusively develops and expands in the bone marrow, and generates devastating bone destruction by osteoclasts (OCs). The bone destruction causes debilitating clinical symptoms including intractable bone pain, disabling multiple fractures, and hypercalcemia. The severity of bone disease correlates with the tumor burden, and is one of the major parameters in Durie and Salmon's clinical staging system. Furthermore, the aggressive features of MM bone lesions have significantly contributed to its poor prognosis despite the recent development of intensive chemotherapeutic regimens.
1,2 Therefore, elucidation of the molecular mechanism of bone destruction and tumor progression is essential for the development of effective therapies to improve survival as well as quality of life of MM patients.
ENHANCEMENT OF BONE RESORPTION
Interactions between receptor activator of nuclear factor-B (RANK) expressed on the surface of cells of the OC lineage and RANK ligand expressed on stromal cells play a key role in the formation and activation of OCs, while osteoprotegerin (OPG), a decoy receptor for RANK ligand secreted from various types of cells, inhibits RANK ligand-RANK signaling. MM cells stimulate OC formation by triggering a coordinated increase in RANK ligand and decrease in OPG in the bone marrow. As shown in FIGURE 1, secretion of OPG from a stromal cell line, KM102, is markedly suppressed by co-culturing with a myeloma cell line, ARH77. Addition of conditioned medium from ARH77 cell culture partially suppressed OPG secretion from KM102 cells, suggesting a partial involvement of humoral mechanism in the suppression of OPG secretion from stromal cells by myeloma cells (FIG. 1) .
MM cells reside in the proximity of stromal cells and activate OCs in bone destructive lesions. We and others have reported that osteoclastogenic C-C chemokines, macrophage inflammatory protein (MIP)-1␣ and (MIP)-1␤ are secreted by most of primary MM cells from patients with multiple osteolytic lesions, and potently induce osteoclastogenesis. 3, 4 The ability of MM cells to secrete these chemokines correlated well with the extent of MM bone lesions as well as levels of bone resorption markers in patients with MM, suggesting a causal role for these chemokines in the development of lytic bone lesions. 5 In osteoclastogenic cultures with bone cells on dentine slices, MM cells enhance both formation and function of OCs. These effects were mostly abrogated by neutralizing antibodies against MIP-1␣ and ␤ in combination, suggesting critical roles for these chemokines in the enhancement of bone resorption. Because the osteoclastogenic activity of (MIP)-1␣ and (MIP)-1␤ is completely inhibited by OPG, and because these chemokines induce RANK ligand expression by a stromal cell line, ST-2, in the presence of a physiological concentration of 1,25-dihydroxyvitamin D 3 , the effects of MM cells on bone resorption are dependent on the stimulation of RANK ligand expression in stromal cells by MIP-1. A portion of MM cells also express RANK ligand on their surface, and concomitantly produce vascular endothelial growth factor (VEGF), which can substitute for M-CSF in the induction of osteoclastogenesis by RANK ligand-RANK interaction. Thus, MM cells potently enhance osteoclastogenesis in the bone marrow microenvironment mainly via the interaction with stromal cells to cause extensive bone resorption and destructive bone lesions. In addition, there may also be a direct interaction of MM cells with OCs and their precursors to directly enhance osteoclastogenesis and bone resorption (FIG. 2) .
ENHANCEMENT OF MYELOMA CELL GROWTH AND SURVIVAL BY OSTEOCLASTS
The fact that MM cells almost exclusively grow and expand in the bone marrow suggests the importance of the bone marrow microenvironment in supporting MM cell growth and survival. Among cell components in the bone marrow microenvironment, roles of stromal cells have been extensively studied. 6, 7 However, MM cells also adhere to OCs, and we have demonstrated that there is a close interaction between MM cells and OCs as well. The growth and survival of MM cells are potently enhanced by a cell-cell interaction with OCs, and the effects of OCs are only partially inhibited by an anti-human interleukin (IL)-6 neutralizing antibody, despite increased production of IL-6 by OCs via the interaction with MM cells. 8 In addition, the growth of human MM cells is enhanced even under interactions with mouse or rabbit OCs. Because mouse and rabbit IL-6 cannot act on human cells, the stimulatory effect of OCs on MM cell growth cannot be explained by the enhancement of IL-6 secretion. Furthermore, prevention of cellular contact between MM cells and OCs completely abolishes the effect of OCs on MM cell growth. 8 Because MM cells become refractory to chemotherapeutic agents in advanced stages when systemic bone destruction develops, there is a possibility that the interaction with OCs may have a protective role against the cytotoxic effects of anticancer agents. Our previous study demonstrates that cell-cell contact with OCs not only enhances the growth of doxorubicin-sensitive MM cells but also causes marked resistance to cytotoxic effects of doxorubicin. 8 These observations are in agreement with clinical findings that MM at advanced stages with extensive osteolytic lesions shows refractoriness to chemotherapies, and suggest that increased osteoclast number and/or activity contributes to aggressiveness or drug resistance of MM cells. Taken together, there is a vicious cycle between MM cells and OCs, and OCs, which are generated and activated by MM cells, not only resorb and destroy bone but also enhance MM cell growth and survival largely via cell-cell interactions with MM cells (FIG. 3) .
ENHANCEMENT OF ANGIOGENESIS BY MYELOMA CELLS
Angiogenesis is enhanced along with osteoclastogenesis in the bone marrow of patients with MM, which has drawn considerable attention as a potential therapeutic target. As mentioned earlier, MM cells secrete high levels of VEGF. In addition, our preliminary results demonstrate that OCs constitutively secrete high levels of an angiogenic noncollagenous matrix protein, osteopontin (OPN), which is known to cooperatively act with VEGF in angiogenesis. Vascular tubule formation is enhanced by an addition of conditioned media from OCs as potently as those from MM cells, which is further enhanced by conditioned media from co-cultures of OCs and MM cells. These results suggest that there are cooperative interactions between OCs and MM cells in stimulating angiogenesis. When antibodies against OPN or VEGF are added alone, they partially inhibit the enhanced angiogenesis by conditioned media from co-cultures of MM cells and OCs, whereas vascular tubule formation is almost completely abrogated when these antibodies are added together (unpublished data). Thus, OCs enhance angiogenesis in concert with MM cells largely through cooperative actions of OPN from OCs and VEGF from MM cells. The angiogenic effect elaborated by the interactions of MM cells with OCs may further facilitate the vicious cycle between bone destruction and MM cell expansion.
SUPPRESSION OF BONE FORMATION
In typical destructive bone lesions of MM, enhanced bone resorption is accompanied by impaired bone formation and mineralization, which causes the well-known "punched-out" lesions on X rays. Analyses of bone turnover by biochemical bone markers also suggest an imbalance of bone turnover with enhanced bone resorption and suppressed bone formation. 5 However, little has been known about the mechanism(s) responsible for the impairment of The increased osteoclastogenesis in turn enhances myeloma cell growth and survival via myeloma cell-osteoclast interaction. Thus, there is a vicious cycle between myeloma cells and osteoclasts to enhance osteoclastic bone resorption and myeloma growth. Although cell-cell contact between myeloma cells and osteoclasts enhances IL-6 and osteopontin production from osteoclasts, the enhancement of myeloma cell growth and survival is only partially dependent upon osteoclast-derived IL-6 and osteopontin. While MIP-1 enhances osteoclastogenesis from monocytic progenitor cells, it also suppresses the formation of myeloid dendritic cells from common progenitor cells, causing suppressed antigen presentation with resultant impairment in immune responses (data not shown). Furthermore, most myeloma cells produce a soluble Wnt antagonist, sFRP-2, which suppresses osteoblast differentiation induced by BMP-2. sFRP-2 appears to play an important role in the defective bone formation caused by myeloma. Therefore, myeloma cells closely interact with bone marrow microenvironment to cause enhanced bone resorption, immune suppression, and impaired bone formation, forming the clinical features with destructive bone lesions and myeloma expansion. bone formation. A canonical Wingless-type (Wnt) signaling pathway has recently been shown to play a critical role in osteoblast differentiation. 9, 10 Wnt proteins are secreted by cystein-rich glycoproteins and are known as regulators of the differentiation of hematopoietic and mesenchymal cells as well as embryonic development. Because conditioned media from MM cells suppress osteoblast differentiation and mineralization, and because several secreted Frizzled-related protein (sFRP) and dickkopf (DKK) family members are known as soluble Wnt antagonists, the expression of sFRP-1, -2, and -3 as well as DKK-1 is examined in MM cells. Various MM cell lines including U266, RPMI8226, and ARH77 secrete only sFRP-2 at protein levels, although sFRP-3 is also expressed at mRNA levels in all these cell lines. Although DKK-1, an inhibitor of an LDL receptor-related protein (LRP)5/6 Wnt coreceptor, was reported to play an important role in the impairment of bone formation by MM, 11 DKK-1 mRNA can be detected only in U266 cells. More importantly, sFRP-2 mRNA and protein can be detected in most MM cells from patients with advanced or terminal stages of MM. In an effort to clarify the role of sFRP-2 in the suppression of bone formation by MM, recombinant sFRP-2 is added to MC3T3-E1 osteoblastic cell cultures together with BMP-2. Exogenous sFRP-2 partially suppresses alkaline phosphatase activity and almost completely blocks mineralized nodule formation enhanced by BMP-2 (submitted for publication). Furthermore, immunodepletion of sFRP-2 restored mineralized nodule formation by MC3T3-E1 cells in the presence of MM cell-conditioned media. These results are consistent with the notion that MM cell-derived sFRP-2 is among the predominant factors responsible for the impairment of bone formation by MM. In contrast to sFRP-2, DKK-1 is preferentially expressed in mature types of MM cells, but barely expressed in plasmablastic or immature types of MM cells. 11 Nevertheless, because MM cells have been shown to secrete factors other than sFRP-2 that are implicated as inhibitors of osteoblast differentiation, including DKK-1, insulin-like growth factor-binding protein 4 and IL-3, sFRP-2 may act in concert with other factors to cause a potent suppression of bone formation in destructive bone lesions. Further elucidation of the mechanism of the development of destructive bone lesions by MM should lead to novel therapeutic approaches to prevent devastating bone destruction and MM cell expansion.
